NXL Nexalin Technology: רווח למניה בשנים עשר החודשים האחרונים

Nexalin Technology, Inc. (NXL) is developing HALO neurostimulation systems in collaboration with clinics to combat depression without medication. The measurement of annual EPS TTM growth visualizes profit dynamics, where the value 23.30 serves as the baseline indicator. However, slow physician adoption and regulatory barriers create risks, while liquidity shortages amid low sales force the company to rely on external capital.
פילוחי מדדים פיננסיים ומדדי שוק עבור Nexalin (NXL)

Analyzing the rolling year-over-year EPS chart allows for an assessment of the financial viability of Nexalin Technology, Inc. (NXL) given its high dependence on a single neurostimulation segment. This indicator calculates the daily ratio of current annual earnings per share to the previous year's, enabling investors to track value creation dynamics and business resilience as clinical trials expand in the US and China.